<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1986 to June 2000, sixty children suffering from <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0005558'>chronic leukemia</z:hpo> (n = 42, 33 of which in resistant relapse), <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic diseases</z:e> (n = 11), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 2, one of which with platelet refractoriness and <z:mp ids='MP_0001914'>bleeding</z:mp>), <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (n = 5) received an haploidentical bone marrow, mismatched for 2-3 HLA loci </plain></SENT>
<SENT sid="1" pm="."><plain>The donor's marrow was treated in vitro with <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> to obtain a functional T <z:mpath ids='MPATH_63'>depletion</z:mpath> (MLC and CTL inhibition, functional blockade of Th1 and Th2) </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of infectious complications and GVHD was similar to that recorded in matched unrelated donor (MUD) transplants </plain></SENT>
<SENT sid="3" pm="."><plain>In situations of high risk of rejection (<z:hpo ids='HP_0005558'>chronic leukemia</z:hpo>, <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic diseases</z:e>) we infused immediately one half of the harvest and then frozen aliquots from the second week </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 25 ALL and 8 AML in resistant relapse, 3 survived, disease-free at 14, 8 and 1 years respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 3 ALL, transplanted during remission, 1 is surviving at 18 months </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 6 <z:mp ids='MP_0005481'>CML</z:mp>, 1 had fractionated bone marrow and is surviving at 3 years, and 5 had standard single dose infusion and died of progression of their disease after rejection of the graft (4) or <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> after complete engraftment (1) </plain></SENT>
<SENT sid="7" pm="."><plain>The 2 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, those with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and 6 of the 10 with <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> died of transplant-related complications or disease progression </plain></SENT>
<SENT sid="8" pm="."><plain>4 patients with <z:hpo ids='HP_0011002'>osteopetrosis</z:hpo> (n = 2), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MLD</z:e> (n = 1), Wiskott Aldrich dis </plain></SENT>
<SENT sid="9" pm="."><plain>(n = 1) survive at 8, 2, 5 and 1.5 years respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In patients transplanted with fractionated marrow GVHD &gt; 2nd grade occurred in 15% </plain></SENT>
<SENT sid="11" pm="."><plain>Only one patient rejected the graft </plain></SENT>
<SENT sid="12" pm="."><plain>Compared with MUD transplantation, mismatched BMT whenever performed in patients in good conditions provides similar outcome and widens the donor availability </plain></SENT>
</text></document>